The head of the Food and Drug Administration (FDA) says he could fast-track a coronavirus vaccine once one is created – even before Phase Three clinical trials end.
FDA Commissioner Stephen Hahn told the Financial Times on Sunday that he could make the move if officials are sure that the benefits of the vaccine outweigh the risks.
“It is up to the [vaccine developer] to apply for authorization or approval, and we make an adjudication of their application,” Hahn told the outlet. “If they do that before the end of Phase Three, we may find that appropriate. We may find that inappropriate, we will make a determination."
Hahn also said if he does so, it will be based solely on scientific data, not political pressure. “This is going to be a science, medicine, data decision,” Hahn said. “This is not going to be a political decision.”